Comment on: “Coxibs Refocus Attention on the Cardiovascular Risks of Non-Aspirin NSAIDs”

dc.creatorUrtasun, Martín Javier
dc.creatorProzzi, Guillermo R.
dc.creatorMarin, Gustavo Horacio
dc.creatorBuschiazzo, Hector Omar
dc.creatorCañás, Martín
dc.creatorDorati, Cristian M.
dc.creatorMordujovich de Buschiazzo, Perla
dc.date.accessioned2018-08-22T19:42:15Z
dc.date.accessioned2018-11-06T12:02:00Z
dc.date.available2018-08-22T19:42:15Z
dc.date.available2018-11-06T12:02:00Z
dc.date.created2018-08-22T19:42:15Z
dc.date.issued2017-12
dc.identifierUrtasun, Martín Javier; Prozzi, Guillermo R.; Marin, Gustavo Horacio; Buschiazzo, Hector Omar; Cañás, Martín; et al.; Comment on: “Coxibs Refocus Attention on the Cardiovascular Risks of Non-Aspirin NSAIDs”; Springer; American Journal Of Cardiovascular Drugs; 17; 6; 12-2017; 493-495
dc.identifier1175-3277
dc.identifierhttp://hdl.handle.net/11336/56698
dc.identifier1179-187X
dc.identifierCONICET Digital
dc.identifierCONICET
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1862483
dc.description.abstractIn a recent issue of the American Journal of Cardiovascular Drugs, Thomas et al. [1] analyzed the cardiovascular safety of cyclo-oxygenase (COX)-2 inhibitors (coxibs). In the Recommendations section of the paper, the authors stated that, based on the results of the PRECISION (Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen) trial [2], celecoxib at moderate doses is not inferior to ibuprofen or naproxen in terms of cardiovascular safety. The PRECISION investigators seem to imply that celecoxib is a ‘cardiovascular safe’ drug, and we would like to challenge this statement with a more detailed analysis of the PRECISION trial.
dc.languageeng
dc.publisherSpringer
dc.relationinfo:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1007/s40256-017-0235-2
dc.relationinfo:eu-repo/semantics/altIdentifier/url/https://link.springer.com/article/10.1007%2Fs40256-017-0235-2
dc.rightshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectCOXIBS
dc.subjectNAPROXEN
dc.subjectCELECOXIB
dc.subjectRISK
dc.titleComment on: “Coxibs Refocus Attention on the Cardiovascular Risks of Non-Aspirin NSAIDs”
dc.typeArtículos de revistas
dc.typeArtículos de revistas
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución